SCHEMBL23609482

SCHEMBL23609482

CNc1n[nH]c2c1CN(C(=O)NC(CN(C)C)c1ccccc1)C2(C)C

nearest known ligand 0.80

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAK4 O96013 16/20 0.80
CDK2 P24941 2/20 0.80
CDK7 P50613 5/20 0.71
CCNH P51946 5/20 0.71
MNAT1 P51948 5/20 0.71
CCNT1 O60563 1/20 0.68
CCNA2 P20248 1/20 0.68
CDK9 P50750 1/20 0.68
CCNA1 P78396 1/20 0.68
PLK4 O00444 1/20 0.67
CHEK1 O14757 1/20 0.67
AURKA O14965 1/20 0.67
GAK O14976 1/20 0.67
RPS6KA5 O75582 1/20 0.67
RPS6KA4 O75676 1/20 0.67
STK16 O75716 1/20 0.67
PAK3 O75914 1/20 0.67
CDKL5 O76039 1/20 0.67
PRKD3 O94806 1/20 0.67
LATS1 O95835 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1205125 0.91 PAK4 (0.83) PAK4CDK2CDK7CCNHMNAT1
SCHEMBL19312151 0.90 PAK4 (0.66) PAK4CDK2CDK7CCNHMNAT1
SCHEMBL25125710 0.90 PAK4 (0.76) PAK4CDK2CDK7CCNHMNAT1
SCHEMBL1205139 0.89 PAK4 (1.00) PAK4CDK2CDK7CCNHMNAT1
SCHEMBL23837237 0.88 PAK4 (0.63) PAK4CDK2CDK7CCNHMNAT1
SCHEMBL1368935 0.87 PAK4 (0.73) PAK4CDK2CDK7CCNHMNAT1
SCHEMBL23837263 0.87 PAK4 (0.62) PAK4CDK2CDK7CCNHMNAT1
SCHEMBL28713458 0.87 PAK4 (0.92) PAK4CDK2CDK7CCNHMNAT1
SCHEMBL28720438 0.87 PAK4 (0.92) PAK4CDK2CDK7CCNHMNAT1
SCHEMBL23837262 0.86 PAK4 (0.61) PAK4CDK2CDK7CCNHMNAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021133601-A1 THE COMBINATION OF CYCLIN DEPENDENT KINASE 7 INHIBITOR AND IMMUNOTHERAPY FOR TREATMENT OF CANCER DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-07-01 WO disclosed